Loading...
•
Dec 31, 2020
Ultragenyx Q4 2020 Earnings Report
Ultragenyx reported Q4 2020 financial results and provided a corporate update.
Key Takeaways
Ultragenyx reported total revenue of $91.5 million for the fourth quarter of 2020. The company had a net loss of $24.0 million, or $0.37 per share. They reaffirmed the 2021 guidance range for Crysvita of $180 million to $190 million.
Total revenue for the fourth quarter of 2020 was $91.5 million.
Crysvita revenue in Ultragenyx territories was $40.4 million for Q4 2020.
Dojolvi product sales were $6.4 million in the fourth quarter of 2020.
Net loss for the fourth quarter of 2020 was $24.0 million, or $0.37 per share.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
The company reaffirms the 2021 guidance range for Crysvita that was provided at the beginning of the year. This range is $180 million to $190 million for the North American profit share region and the other regions where product sales are recognized (Latin America and Turkey).
Positive Outlook
- Initiate a Phase 3 study for DTX401 for Glycogen Storage Disease Type Ia (GSDIa) in the first half of 2021.
- Initiate a Phase 3 study for DTX301 for Ornithine Transcarbamylase (OTC) Deficiency in the second half of 2021.
- Initiate a Phase 1/2/3 study for UX701 for Wilson disease in the first half of 2021.
- Resume enrollment and dosing in the Phase 1/2 study for GTX-102 for Angelman Syndrome in the first half of 2021.
- Conduct a Phase 2/3 study in pediatric patients for UX143 (setrusumab) for Osteogenesis Imperfecta, anticipated in second half of 2021.
Challenges Ahead
- Uncertainty and potential delays related to clinical drug development.
- Smaller than anticipated market opportunities for the company’s products and product candidates.
- Manufacturing risks.
- Competition from other therapies or products.
- Effects from the COVID-19 pandemic on the company’s clinical activities, business and operating results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income